Latest News and Press Releases

PETALUMA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique,...

PETALUMA, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quarterly Net Loss Reduced by 53% Compared to Prior YearYTD Net Loss Reduced by 82% Compared to Prior YearTotal YTD Revenues of $14.4 Million...

PETALUMA, Calif., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique,...

PETALUMA, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the closing of a public offering of 446,577 shares of common stock at a public...

PETALUMA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of its previously announced “best efforts” public offering of shares of...

PETALUMA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the launch of a “best efforts” public offering of shares of its common stock. Dawson...

Quarterly and YTD Reduction in Net Loss Compared to Prior Year PETALUMA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company...

Agreement with CEO and Interim CFO Bubba Sandford endsAmy Trombly Appointed as Interim CEO John Dal Poggetto Appointed as New CFO PETALUMA, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Sonoma...

Strong Quarter-Over-Quarter Performance 26% Increase in U.S. Product Revenue46% Increase in Dermatology Revenue23% Reduction in Operating Expenses PETALUMA, Calif., Aug. 13, 2019 (GLOBE...

PETALUMA, Calif., July 12, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique,...